ESMO GI 2025

July 02-05, 2025
Barcelona, Spain

The ESMO Gastrointestinal Cancers Congress 2025

Explore more Oncology congress materials

Results(2)

Oncology

Prognostic Factors Associated With Survival for Patients With HER2-Positive Gastro-Oesophageal Adenocarcinoma

Author(s): John Bridgewater, Wayne Su, Javier Sabater et al.

Antitumour Activity and Safety of First-Line Zanidatamab + Cisplatin-Gemcitabine in Patients With HER2-Expressing Biliary Tract Cancer

Author(s): Do-Youn Oh, Keun-Wook Lee, Bruce Lin et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.